Disolf PHI

Each enteric coated tablet of DISOLF contains ...

• Bioactive protein fraction DLBS1033 250 mg

• Bioactive protein fraction DLBS3233 500 mg

• Bioactive protein fraction DLBS1033 490 mg

• Bioactive protein fraction DLBS1033 500 mg

DISOLF is containing bioactive fraction. What is the benefit of bioactive fraction compare to extract ?

• Bioactive fraction has a higher purity, also the most active and potent proteins for the best clinical efficacy and safety

• Bioactive fraction has a higher volume than crude extract

• Bioactive fraction always has an equal efficacy with chemical substances

• Bioactive fraction is always having a better solubility

Systematic screening methodology that dedicated to find the most active and potent candidate for DLBS products, including DISOLF is called ...

• Advanced Extract Technology (AET)

• Active Chemistry Selection System (ACSS)

• Gradual Extraction Technology (GET)

• Tandem Chemistry Expression Bioassay System (TCEBS)

These following conditions are at risk of Atherothrombosis, except ...

• People with Diabetes Mellitus

• People with Hyperlipidemia

• People with extreme diets

• People with history of vascular events

DISOLF has the quadruple actions. These following statements show the action of DISOLF, except ...

• Anti-platelet aggregation

• Fibrinogenolytic

• Clot lysis

• Erythrocytic